Structure of JPMA
Promotes the Compliance of JPMA Member Companies, maintains/manages the JPMA Code of Practice, and supports the JPMA Member Companies' activities on the compliance of code.
Optimizes dissemination of information on ethical drugs and reviews member companies' product information brochures, advertisements, and related publishes information.
To respond promptly to the changes in the environment surrounding the Pharmaceutical industry, conducts studies of industrial development, medical innovation, the tax program for research and development, and other issues relevant to industrial policy. Also examines any urgent matters to which other standing committees may not be able to respond.
Aims for accoutable and efficient distribution of drug products and related organizations and governmental bodies. Undertakes surveys and studies on drug product distribution for policy and strategy proposal.
Promotes appropriate measures for research and development of new drugs, post-marketing safety measures, and appropriate use of drugs. Proposes policies and strategies based on research on technology, regulatory science and regulation etc.
Joins the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH),in which many regulatory authorities and global organization of pharmaceutical industries bring together to develop harmonized guidelines.
Conducts surveys and studies on good manufacturing practice(GMP), and pharmaceutical manufacturing technology with subjects related to their physical properties. Establishes and promotes measures to improve reliability and quality of pharmaceutical products. Develops harmonized guidelines on quality topics within the framework of trilateral harmonization(Japan, US, and EU) in collaboration with ICH Project Committee.
Presents recommendations to governmental bodies on biopharmaceutical-related policies concerning the infrastructure development for promoting R&D of biotechnology-based drugs. Investigates technical issues in R&D, manufacturing, post-marketing surveillance, and recommends the relevant ministries/agencies on improvements.
Investigates problems in implementing the Pharmaceutical and Medical Device Act, the approval process of drugs, and safety measures in pharmaceutical regulations, and recommends the pharmaceutical agencies on policies regarding to effective corporate activities and swift drug approval etc. from stand points of R&D-based pharmaceutical companies.
Coodinates with relevant gorvernmental bodies and other organizations to Promote an international competitiveness of Japanese Pharmaceutical industry. Proposes new policies and strategies to establish a virtual cycle of creation, protection, and utilization of intellectual property worldwide in Life Science.
Improves the infrastructure for medicinal research including introduction of new technology. Promotes industry-academia-government coalitions to stimulate transfer technology from academia to the pharmaceutical industry and train Professionals.
Based upon our three core concepts of International Business Development, International Policy Convergence and International Social Contribution, deepen collaboration with regulatory authorities as well as R & D based industry associations in the relevant region, country and economy, we continue to implement activities for those challenges the industry and the member companies are facing internationally.
Defines best practice models for global envaironment preservation and occupational safety and health management. Supports member companies' measures on the environment and safety. Prepares and publishes JPMA Environmental Reports annually, and conducts dialogues with outside organizations.
Develops activities to improve public recognition and understanding of medicines and the pharmaceutical industry. Takes action to facilitate adoption and implementation of JPMA proposals and policies.
Builds better relationships with patient groups and actively exchanges opinions with them, and disseminates information and executes policies that reflect the patients perspective.
Furthermore, endeavors to make well-known the "JPMA Code of Practice on Relationships between the Pharmaceutical Industry and Patient Groups".
Investigates and advises on apropriate ways to provide the public with drug information and on how product information departments should operate, to gain more reliability and recognitions, thus contributing to Patient-oriented Health Care.
Conducts research on medium to long term strategic policies and related topics for the development of the pharmaceutical industry and its contribution to society.